Full body MRI
The Royal Australian and New Zealand College of Radiologists (RANZCR) defines whole body MRI as MRI of the head, neck, chest, abdomen, and pelvis.[1] For people without symptoms, the American College of Radiology (2023) does not believe the evidence justifies recommending screening, RANZCR (2025) does not recommend it, and the Canadian Association of Radiologists (2025) opposes it.[1][2][3]
What a whole-body MRI covers
The Royal Australian and New Zealand College of Radiologists (RANZCR) defines whole body MRI as MRI of the head, neck, chest, abdomen, and pelvis, and states that total body MRI is a synonym.[1] A 2026 article in Canadian Family Physician describes whole-body MRI as commonly from head to mid-thigh.[4]
The abstract of a study of people with Li-Fraumeni syndrome says whole-body MRI can image from vertex to toes in a single examination.[5]
What pooled studies of people scanned without a medical reason found
A 2026 systematic review and meta-analysis pooled 17 studies in which 18,043 people had a whole-body MRI without an evidence-based medical reason.[6] Eleven of the studies, covering 4,463 people, reported cancers confirmed by pathology, and the pooled rate was 1.4% (95% CI 0.9% to 2.2%).[6]
The review states that the included studies were "low quality, heterogeneous, with some evidence of publication bias," and that diagnostic yield "is a surrogate for clinically meaningful outcomes such as mortality reduction and net harm-benefit balance, which remain unknown."[6]
The 2026 review states that all of the studies came from non-US health care systems across East Asia, Western Europe and the Middle East, that several involved employer-sponsored, private or otherwise selected cohorts rather than representative community samples, and that only 7 of 17 studies explicitly described their populations as asymptomatic.[6]
The 2026 review was funded in part through a National Institutes of Health and National Cancer Institute Cancer Center Support Grant, and one author reported consultation work for a company.[6]
A second meta-analysis, of 10 studies in 9,024 people without symptoms, reported a pooled rate of confirmed cancer of 1.57% (95% CI 1.22% to 2.03%).[6][7] Its authors concluded: "Although WB-MRI shows potential as an opportunistic non-invasive cancer detection tool, modest detection rates, frequent incidental findings, unstandardized protocols, and lack of long-term outcome or cost-effectiveness data limit its current clinical utility."[7] The abstract also reports that results held up in sensitivity and meta-regression analyses, that no significant subgroup differences or publication bias were found, and that most studies had a moderate to serious risk of bias, while the 2026 review found signs of publication bias in its cancer results.[6][7] We read the abstract of this analysis, not the full paper.[7] The two reviews may include some of the same studies.[6][7]
An earlier review of 12 studies and 6,214 examinations in asymptomatic people from the general population reported that cancer was confirmed in 1.1%, that 95% of people scanned had at least one abnormal finding, and that 30% had a finding needing further investigation.[8] Of 17,961 abnormal findings reported, 91% were benign and 9% were oncologically relevant.[8] The authors wrote that the studies "are too heterogeneous to draw impactful conclusions regarding efficacy," and reported no funding and no competing interests.[8] We read the abstract only.[8]
Findings by how a finding is defined
In a 2026 systematic review and meta-analysis of 17 studies of whole-body MRI in people without an evidence-based indication, any finding was reported in 78.0% of 17,115 people in 13 studies (95% CI 44.9% to 93.9%).[6] A finding that was not cancer but called for follow-up was reported in 14.8% of 17,167 people in 13 studies (95% CI 6.6% to 30.0%).[6] Of the people with such a finding, 58.2% went on to more laboratory tests or imaging (95% CI 36.0% to 77.5%) and 20.8% had a procedure such as an endoscopy or a biopsy (95% CI 9.7% to 39.2%), in 11 studies.[6] The review states that between-study heterogeneity was substantial (I² above 90% across most analyses) and that the confidence intervals are correspondingly wide and "should not be interpreted as precise population-level benchmarks."[6]
The authors of the 2026 systematic review concluded: "The majority of WBMRIs performed in a population without an evidence-based indication result in findings that are normal or do not require follow-up. Clinical outcomes associated with discovery of actionable lesions are unknown." WBMRI means whole-body MRI.[6]
Ten of the 17 studies (58.8%) in a 2026 systematic review of whole-body MRI without an evidence-based indication used protocols that included contrast imaging.[6] The Canadian Association of Radiologists describes screening scans as "non-contrast, generalized, and not optimized for any condition or anatomy".[3]
A 2019 systematic review of 12 studies of 5,373 asymptomatic adults without known disease, syndrome or genetic mutation reported critical and indeterminate incidental findings together in 32.1% (95% CI 18.3% to 50.1%), critical findings in 13.4% (95% CI 9.0% to 19.5%) and indeterminate findings in 13.9% (95% CI 5.4% to 31.3%).[9] Critical or indeterminate findings that were verified were 12.6% (95% CI 3.2% to 38.8%).[9] The authors reported high between-study heterogeneity (I² 95.6% to 99.1%) and wrote: "Verification data are lacking."[9]
In the same 2019 review, the combined share of critical and indeterminate findings was higher in studies whose protocols included (cardio)vascular or colon MRI (49.7%, 95% CI 26.7% to 72.9%) than in studies that did not (23.0%, 95% CI 5.5% to 60.3%; P < 0.001).[9]
A 2019 systematic review reported that six of its 12 studies gave false-positive findings, with a pooled proportion of 16.0% (95% CI 1.9% to 65.8%), and that "Only one study reported false-negative findings, with a proportion of 2.0%."[9] The 2026 review of 17 studies could not calculate a false-positive rate because the studies did not report the results of follow-up tests.[6] We read the 2019 review as an abstract only.[9]
In a German research cohort of 2,500 adults, 904 (36.2%) had at least one whole-body MRI finding of potential clinical relevance, and findings were disclosed to 787 participants (31.5%).[10] Of the 1,052 disclosed findings, 62 (5.9%) were described as malignant, 383 (36.4%) as benign and 607 (57.7%) as unclear.[10] The abstract does not say how many were later confirmed.[10] These were research scans in volunteers, not a consumer service.[10]
In a private hospital in Poland, 666 non-contrast whole-body MRI scans (451 people aged 50 or younger and 215 older) found 3,375 incidental findings in 659 people (98.9%).[11] The authors classified 15 lesions (0.4%) as significant and requiring treatment, and malignant or possibly malignant lesions were found in seven people.[11]
| Definition of a finding | Study or review | People | Share with the finding |
|---|---|---|---|
| Any finding reported | 2026 review of 17 studies[6] | 17,115 people in 13 studies | 78.0% (95% CI 44.9 to 93.9) |
| A finding that was not cancer and called for follow-up | 2026 review of 17 studies[6] | 17,167 people in 13 studies | 14.8% (95% CI 6.6 to 30.0) |
| Critical or indeterminate incidental finding | 2019 review of 12 studies[9] | 5,373 adults without symptoms | 32.1% (95% CI 18.3 to 50.1) |
| Finding of potential clinical relevance | German research cohort, 2013[10] | 2,500 adults | 36.2% (904 people) |
| At least one abnormal finding | 2020 review of 12 studies[8] | 6,214 examinations | 95% (no interval reported) |
| Any incidental finding | Private hospital in Poland, 2014[11] | 666 non-contrast scans | 98.9% (659 people) |
Each row counts a different kind of finding in a different group of people, so the rows cannot be added together or ranked against each other.
What has not been studied
In searches of PubMed, Europe PMC, ClinicalTrials.gov, ISRCTN and the EU Clinical Trials Register on October 8, 2026, we found no completed randomized trial that compares whole-body MRI screening with no screening in people without symptoms and reports a health outcome.
In searches of PubMed and Europe PMC on October 8, 2026, we found no study that compares deaths or survival between people without symptoms who had whole-body MRI screening and people who did not.
On October 8, 2026, ClinicalTrials.gov listed an observational study of whole-body MRI screening with a planned 100,000 participants, an estimated primary completion in January 2034 and an estimated study completion in January 2037.[12] The record lists a sponsor classed as industry and a named collaborator, and it had posted no results.[12] The Cochrane Database of Systematic Reviews lists a 2026 protocol for a review of whole-body MRI or CT screening in adults without symptoms; a protocol sets out a plan and has no findings.[13]
What radiology societies say
For people without symptoms, the American College of Radiology (statement of April 17, 2023) does not believe the evidence justifies recommending total body screening, the Royal Australian and New Zealand College of Radiologists (position statement of July 4, 2025) does not recommend it, and the Canadian Association of Radiologists (policy statement of June 2025) opposes it.[1][2][3]
In a statement dated April 17, 2023 on screening total body MRI, the American College of Radiology (ACR) said it "does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms, risk factors or a family history suggesting underlying disease or serious injury". The statement also says: "To date, there is no documented evidence that total body screening is cost-efficient or effective in prolonging life." The ACR said it will continue to monitor scientific studies concerning the utility of screening total body MRI.[2]
The Canadian Association of Radiologists, in a policy statement dated June 2025, "opposes the use of whole-body or full-body magnetic resonance imaging (MRI) as a screening tool in asymptomatic individuals, outside of specific, evidence-based clinical indications." The statement says: "There is no compelling evidence from high-quality studies demonstrating that whole-body MRI screening in asymptomatic individuals improves long-term health outcomes, reduces morbidity or mortality, or leads to better health at the population level."[3]
The Royal Australian and New Zealand College of Radiologists, in a position statement dated July 4, 2025, states: "Currently there is no evidence that demonstrates significant improvement in health outcomes when performing whole body MRI screening in an asymptomatic population. The College does not recommend performing whole body MRI screening in asymptomatic patients who do not have a previously diagnosed malignancy or a cancer predisposition syndrome." The statement adds that total body imaging, including whole-body MRI, has a role as a diagnostic investigation for selected patients with malignancies or cancer predisposition syndromes.[1]
RANZCR also states: "There is no evidence that whole body MRI screening in the asymptomatic patient has any net effect, positive or negative, on patient morbidity or mortality."[1]
RANZCR states that, to date, "no study has been performed that rigorously investigates the impact on disease-specific survival following whole body MRI in asymptomatic patients without specific risk factors," and that no study has been performed to confirm that a negative whole body MRI excludes significant disease five or more years later. It also states: "False reassurance from whole body MRI has the potential for significant negative health outcomes."[1]
In an Istanbul study of 576 asymptomatic adults who had a non-contrast whole-body MRI between 2009 and 2020, 15 (2.6%) had cancers, 28 (4.8%) had intracranial aneurysms and 65 (11.2%) received a treatment triggered by the scan.[14] Record review and interviews identified 16 people (2.8%) with false-negative findings, five of whom had cancer.[14] We read this study as an abstract only.[14]
A Canadian Family Physician article
A 2026 article by three authors in Canadian Family Physician states: "There are no randomized controlled trials (RCTs) comparing patients who received WBMRI for cancer screening to patients who did not." It also states: "Mortality data are not available." The authors write that whole-body MRI for cancer screening in asymptomatic individuals "should not be encouraged." WBMRI means whole-body MRI. The authors declared no conflicts of interest.[4]
Talk to a licensed clinician about whether a whole-body MRI is appropriate for you.
Follow-up tests, biopsies and other possible harms
In a German population study, 3,371 of 6,753 participants in the biopsy analysis had a research whole-body MRI, and 1,022 of them (30.3%) were told of an incidental MRI finding.[15] Being told of an MRI finding was associated with more biopsies (incidence rate ratio 2.17, 95% CI 1.76 to 2.68).[15]
Across the whole study group, pathology records from one university department showed 938 biopsy reports in the two years before the examination and 1,333 in the two years after.[15] Both before and after the examination, most biopsies showed no malignancy or tumor.[15] Biopsies that found cancer also became more frequent after the examination, and the authors wrote that "the clinical benefit of the earlier detection of malignancies is uncertain."[15] The scans were research scans with optional contrast components.[15]
The abstract of the same study reports that malignant biopsy results were more frequent after the examination than before it across the cohort (rate ratio 1.74, 95% CI 1.27 to 2.42), and that nonmalignant biopsy results increased more in participants who were told of a finding (rate ratio 1.39, 95% CI 1.22 to 1.58) than in those who were not (rate ratio 1.09, 95% CI 0.85 to 1.38).[15] The authors listed as a limitation the missing direct link between an incidental finding and the observed biopsies.[15] Biopsy data came from one department and were available for 22% of participants living near the study center and 7.5% of those living 40 to 89 kilometers away.[15]
The German study states: "Whole-body MR imaging was supported by a joint grant from Siemens Healthcare, Erlangen, Germany, and the Federal State of Mecklenburg-Vorpommern." It also reports support from Bayer Healthcare for MR mammography research and from the Deutsche Forschungsgemeinschaft for the incidental-findings work, and the authors declare that they have no conflict of interest.[15]
Costs
In a German cohort study with insurance claims, 5,019 people were analyzed, of whom 2,969 had a research whole-body MRI.[16] Mean outpatient costs over 24 months were €2,839 (95% CI 2,741 to 2,936) with the MRI and €2,547 (95% CI 2,424 to 2,671) without it.[16] After weighting for baseline differences, the estimated increase was €295 per person (95% CI €134 to €456).[16] The comparison was observational, the costs are from German statutory health insurance, and we read the abstract only.[16]
How people feel afterward
Studies of how people feel after a whole-body MRI do not agree.[17] In a German survey of 405 people who had been sent a notice of an incidental finding after a research scan, 116 (28.6%) reported moderate to severe psychological distress afterwards, and the authors wrote of "numerous adverse consequences concerning the communication of incidental findings and false expectations about the likely potential benefits of whole-body-MRI," despite high satisfaction among most participants.[17] We read this study as an abstract.[17]
A later analysis from the same research program compared 2,188 scanned people with unscanned cohort members (4,420 in all) about two and a half years later and found a difference in depression score of 0.08 per year (95% CI minus 0.03 to 0.18).[18] Its authors wrote that whole-body MRI "can be implemented in a population-based study without long-term effects on QoL indicators and depressive symptoms," and added: "This does not exclude the possibility of effects on more subtle psychosocial outcomes, such as health concerns or health behaviour, all of which require further attention."[18] We read this study as an abstract.[18]
In a study of 3,603 customers of six commercial clinics in Germany and the Netherlands who had an MRI and cardiological screening package, 72.0% reported reassurance and 83.0% reported insight into their health, while 5.0% reported feeling insecure about their health and 6.2% worried more about their health as a consequence of screening.[19] We read this study as an abstract.[19]
In the study of commercial clinic customers, several authors declared research grants or personal fees from a company, one author is affiliated with that company, and two are employed by an organization that was paid to conduct the study.[19]
If you have a medical emergency, call 911. Problems with medical devices, including imaging equipment, can be reported to FDA through MedWatch.
People with Li-Fraumeni syndrome
A 2020 guideline for the Li-Fraumeni and heritable TP53-related cancer syndromes, published in the European Journal of Human Genetics, lists for adults with these syndromes a surveillance schedule that includes, every year, a clinical examination, whole-body MRI, breast MRI in females from age 20 until 65 and brain MRI until age 50.[20]
A 2017 pooled analysis of 578 people with a germline TP53 variant, from 13 research cohorts in 6 countries, estimated that a baseline whole-body MRI found a new localized cancer in 7% (95% CI 5% to 9%).[21] A 2025 systematic review and updated meta-analysis of 703 people with Li-Fraumeni syndrome, in 11 studies, reported an overall cancer detection rate of 6% (95% CI 5% to 8%).[22] We read these sources as abstracts.[21][22]
These figures describe people with a known TP53 gene variant and do not apply to people without one.
Coverage
Coverage varies by plan and can depend on the reason it is ordered. Confirm coverage, and any prior authorization, with your insurer.
Provider directory
Some facilities require a clinician's order. Requirements vary.
Related diagnostics
References
- The Royal Australian and New Zealand College of Radiologists. Whole Body MRI Screening in Low-Risk Patients, Position Statement v1.1. Date of Approval 4 July 2025. https://ranzcr.com/college/document-library/2024-position-statement-on-whole-body-mri. Accessed 2026-10-14.
- American College of Radiology. ACR Statement on Screening Total Body MRI. April 17, 2023. https://www.acr.org/News-and-Publications/Media-Center/2023/ACR-Statement-on-Screening-Total-Body-MRI. Accessed 2026-10-14.
- Canadian Association of Radiologists. Whole-Body MRI Screening in Asymptomatic Individuals: Policy Statement. Approved by the Board of Directors, June 2025. https://car.ca/wp-content/uploads/2025/09/CAR-Policy-Statement-Whole-Body-MRI-Screening-in-Asymptomatic-Individuals.pdf. Accessed 2026-10-08.
- Maplethorpe E, Low G, Kolber MR. Whole-body magnetic resonance imaging for cancer screening. Can Fam Physician. 2026;72(7-8):471. doi:10.46747/cfp.720708471. PMID 42527324. https://pmc.ncbi.nlm.nih.gov/articles/PMC13431211/. Accessed 2026-10-14.
- Finn E and others. SIGNIFIED: whole-body MRI screening in Li-Fraumeni syndrome in the UK. ESMO Open. 2026. doi:10.1016/j.esmoop.2025.106045. PMID 41740205. https://pubmed.ncbi.nlm.nih.gov/41740205/. Accessed 2026-10-08.
- Ahsan MD, Frontera N, Gurram A, and others. The Diagnostic Yield of Whole-Body MRI as a Multi-disease Screening Modality: A Systematic Review and Meta-analysis. J Gen Intern Med. 2026. doi:10.1007/s11606-026-10802-y. PMID 42823587. Accessed 2026-10-08.
- Martins da Fonseca J, Trennepohl T, Pinheiro LG, and others. Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis. Eur Radiol. 2025. doi:10.1007/s00330-025-11976-5. PMID 40884613. https://pubmed.ncbi.nlm.nih.gov/40884613/. Accessed 2026-10-14.
- Zugni F, Padhani AR, Koh DM, Summers PE, Bellomi M, Petralia G. Whole-body magnetic resonance imaging (WB-MRI) for cancer screening in asymptomatic subjects of the general population: review and recommendations. Cancer Imaging. 2020;20(1):34. doi:10.1186/s40644-020-00315-0. PMID 32393345. Accessed 2026-10-08.
- Kwee RM, Kwee TC. Whole-body MRI for preventive health screening: A systematic review of the literature. J Magn Reson Imaging. 2019;50(5):1489-1503. doi:10.1002/jmri.26736. PMID 30932247. Accessed 2026-10-14.
- Hegenscheid K, Seipel R, Schmidt CO, and others. Potentially relevant incidental findings on research whole-body MRI in the general adult population: frequencies and management. Eur Radiol. 2013;23(3):816-826. doi:10.1007/s00330-012-2636-6. PMID 22911290. Accessed 2026-10-08.
- Cieszanowski A, Maj E, Kulisiewicz P, and others. Non-contrast-enhanced whole-body magnetic resonance imaging in the general population: the incidence of abnormal findings in patients 50 years old and younger compared to older subjects. PLoS One. 2014;9(9):e107840. doi:10.1371/journal.pone.0107840. PMID 25259581. Accessed 2026-10-08.
- ClinicalTrials.gov. Record NCT06212479, observational study of whole-body magnetic resonance imaging. https://clinicaltrials.gov/study/NCT06212479. Accessed 2026-10-14.
- Chen Z, Johansson M, Albarqouni L, Woloshin S, Jørgensen KJ. Whole-body magnetic resonance imaging (MRI) or computed tomography (CT) screening for reducing morbidity and mortality from multiple diseases in asymptomatic adults (protocol). Cochrane Database Syst Rev. 2026. doi:10.1002/14651858.CD016234. PMID 42639816. Accessed 2026-10-08.
- Basar Y, Alis D, Tekcan Sanli DE, Akbas T, Karaarslan E. Whole-body MRI for preventive health screening: Management strategies and clinical implications. Eur J Radiol. 2021;137:109584. doi:10.1016/j.ejrad.2021.109584. PMID 33596499. Accessed 2026-10-08.
- Richter A, Sierocinski E, Singer S, Bülow R, Hackmann C, Chenot JF, Schmidt CO. The effects of incidental findings from whole-body MRI on the frequency of biopsies and detected malignancies or benign conditions in a general population cohort study. Eur J Epidemiol. 2020;35(10):925-935. doi:10.1007/s10654-020-00679-4. PMID 32860149. https://pmc.ncbi.nlm.nih.gov/articles/PMC7524843/. Accessed 2026-10-14.
- Schmidt CO, Sierocinski E, Baumeister S, Hegenscheid K, Völzke H, Chenot JF. Effects of whole-body MRI on outpatient health service costs: a general-population prospective cohort study in Mecklenburg-Vorpommern, Germany. BMJ Open. 2022;12(1):e056572. doi:10.1136/bmjopen-2021-056572. PMID 34996801. Accessed 2026-10-08.
- Schmidt CO and others. Psychosocial consequences and severity of disclosed incidental findings from whole-body MRI in a general population study. Eur Radiol. 2013;23(5):1343-1351. doi:10.1007/s00330-012-2723-8. PMID 23239059. Accessed 2026-10-14.
- Schmidt CO and others. Impact of whole-body MRI in a general population study. Eur J Epidemiol. 2016;31(1):31-39. doi:10.1007/s10654-015-0101-y. PMID 26597793. Accessed 2026-10-14.
- Hommes D, Klatte D, Otten W, Beltman M, Klass G, Zand A, Sprangers R. Health outcomes and experiences of direct-to-consumer high-intensity screening using both whole-body magnetic resonance imaging and cardiological examination. PLoS One. 2020;15(11):e0242066. doi:10.1371/journal.pone.0242066. PMID 33216779. Accessed 2026-10-14.
- Frebourg T, Bajalica Lagercrantz S, Oliveira C, and others. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020. doi:10.1038/s41431-020-0638-4. PMID 32457520. Accessed 2026-10-14.
- Ballinger ML, Best A, Mai PL, and others. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017;3(12):1634-1639. doi:10.1001/jamaoncol.2017.1968. PMID 28772291. Accessed 2026-10-14.
- Dacoregio MI, Abrahao Reis PC, Goncalves Celso DS, and others. Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis. Eur Radiol. 2025;35(2):643-651. doi:10.1007/s00330-024-10983-2. PMID 39075300. Accessed 2026-10-08.